Page 3 - Heman Chao News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Helix BioPharma Corp plans management shakeup in September with CEO Herman Chao stepping down
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
NA Proactive news snapshot: Empower Clinics Inc, Kintara Therapeutics Inc, Perma-Fix Environmental Services Inc, Safe-T Group Ltd, Exactus Inc, American Battery Metals Corporation, Vox Royalty Corp, Steppe Gold Limited, ImagineAR Inc, Gevo Inc
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
NA Proactive news snapshot: Bioasis Technologies Inc, BioSig Technologies Inc, Empower Clinics Inc, Kintara Therapeutics Inc, Perma-Fix Environmental Services Inc, Safe-T Group Ltd, Exactus Inc, American Battery Metals Corporation, Vox Royalty Corp, Stepp
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
Helix BioPharma Corp Announces Changes to the Company s Board of Directors and Management
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Helix BioPharma Corp raises C$10M in institutional investor funding from Lind Partners
Helix BioPharma Corp (TSE:HBP) (OTCMKTS:HBPCF) (FRA:HBP) CEO Heman Chao tells Proactive it will receive up to C$10 million in financing from New York based institutional investment fund Lind Global Macro Fund, LP through the issuance of convertible securities. Chao says the first tranche of C$3.5 million is expected to be issued on or around May 12, with the second tranche of up to an additional C$6.5 million available to be received thereafter. The funds will be used towards advancing its Phase lb/ll pancreatic cancer clinical study.